Metachronous Lung Cancer Developing after 11 Years of Chemo-Radiotherapy in a Patient with Non-Small Cell Lung Carcinoma

Onur Derdiyok*, Selma Aydogan, Murat Kavas, Cansel Atinkaya, Irfan Yalcinkaya

Department of Thoracic Surgery, Sureyyapasa Chest Diseases and Thoracic Surgery Training and Research Hospital, Istanbul, Turkey

Email: *onur_derdiyok@hotmail.com

Abstract
The success rate of the chemo-radiotherapy is low for the patients with lung cancer. The risk of second primary malignancy (SPM) in lung cancer survivors is also not well reported in the literature. A 77-year-old male patient was given chemo-radiotherapy (KT_RT) 11 years ago because of the low respiratory function of the non-small cell lung cancer in the right lung. He applied to hospital for complaining cough. NSCLC was diagnosed and doctors performed left lower lobectomy to the patient. We presented the case in which the patient was cured after chemo-radiotherapy which is an extremely rare condition and the development of a second tumor 11 years later.

Keywords
Metachronous, Lung Cancer, Thoracic Surgery

1. Introduction
More than one or two primary lung cancers may develop synchronously or metachronically in the lung. Previous research showed that, regardless of developing time and location, the majority of the second primary lung malignancies are the same histological type. However, the recurrence of the second primary lung malignant tumor is very rare, especially with different histologic features. Metachronous tumors are different histologic type for the diagnosis or histologic type is the same if the disease-free survival rate is more than 2 years. The disease is detected in situ. The second cancer is in a different lobe or lung, or no metastasis. For the synchronous and metachronous tumors, the criteria defined by Martini, Melamed in 1975 and Antakli in 1995 are used [1]. We presented the case in which the patient was cured after chemo-radiotherapy and the develop-
ment of a second tumor 11 years later.

2. Case

A 71-year-old man applied to our clinic for complaints of shortness of breath and numbness on the right hand 11 years ago. His history included tuberculosis treatment 20 years ago and 30 pack/year smoking history. He smoked 13 years ago. He had coronary artery disease. In 2004, the patient was diagnosed as squamous cell lung carcinoma by biopsy from the right upper lobe with fiberoptic bronchoscopy (FOB). However, the patient was treated with adjuvant chemotherapy paclitaxel, carboplatin cure and definitive radiotherapy due to limitation of pulmonary function tests. The patient then admitted to hospital complaining cough in 2015. His blood pressure was 130/85 mm/Hg, pulse was 90/min, fever was 36.5˚C and respiratory rate was 26/min. Laboratory parameters were within normal limits. Thoracic computed tomography (CT) revealed a nodule in the left lower lobe that was uniformly sized and 19 mm in size (Figure 1). No endobronchial lesions were seen on the FOB examination. The nodule was found to have an SUV-max value of 18 at positron emission computed tomography (PET-CT). In pulmonary function tests were FVC: 3.58 lt, 103%; FEV1: 2.73 lt, 89%. Left lower lobectomy was performed when squamous cell lung cancer was reported on frozen examination. The patient did not receive chemo-radiotherapy. He did well at 17-month follow-up.

3. Discussion

Pulmonary resection is currently the most effective treatment for patients with non-small cell lung cancer. However, patients undergoing curative surgical resection for primary lung cancer are also at risk of secondary primary lung cancer. Metachronous second primary lung cancer risk is 1% - 2%/patient/year in patients after lung cancer resection [2].

A literature on curative therapy after chemo-radiotherapy has not been found. Our case is important both in this respect and in terms of observing metacronous tumor development coexistence after 11 years. It is estimated that 4% to 10% of all patients with non-small cell lung cancer (NSCLC) later have

![Figure 1](attachment:image.png)

**Figure 1.** Thorax computed tomography (CT) shows a smoothly confined left lower lobe, nodule with a dimension of 22 mm.
metachronous [3]. The standard surgical treatment for patients with resectable small cell lung cancer is pulmonary lobectomy. There is no definitive guideline for surgical treatment for metachronous second primary lung cancer [1]. If the cardiopulmonary reserve is sufficient in metachronous tumors and if the previous operation is not pneumonectomy, lobectomy can be performed.

Metachronous tumors were found to have a 5-year survival rate of 33% and a 10-year survival rate of 20%, compared with primary lung cancers, but higher than metastases and synchronous tumors in resected metachronous tumors [4]. In recent years, introduction of various diagnostic methods and the development of new therapeutic agents and techniques may lead to recurrence or new cancers in one third of patients, especially in stage I non-small cell lung cancer. For this reason, the risk of second cancer increases as patients who initially appear to be early-stage lung cancer survive [5].

A common genetic history is common between the first lung cancer and the second primary lung cancer. Thus, the majority of secondary lung cancer is similar to the lung cancer initially presented in the histological type [6].

As a result, it should be reminded that metachronous or synchronous lung cancer may develop after the cured primer lung cancer treatment. The patients should follow for a long time for the risk of second primary lung tumours.

References


